Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, which enables the company to commence U.S. manufacturing of its proprietary Alpha DaRT technology in 2026. The company's strong cash position further supports its capability to develop innovative solutions in oncology, targeting a highly unmet medical need. Despite a net loss of $11.7 million, slightly higher than expected, the potential effectiveness of Alpha DaRT in producing systemic responses from localized treatment suggests promising long-term growth prospects for Alpha Tau Medical.

Bears say

Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting the ongoing financial challenges the company faces as it operates at a clinical stage. Significant risks loom over its Alpha DaRT technology, including potential failure in clinical trials, the inability to secure regulatory approval in the U.S., and challenges related to market size and competition, all of which could hinder potential commercial success. Additionally, the company may face dilution risk that could undermine shareholder value, further contributing to a negative outlook for its stock.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.